Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer

Cancer Letters, 02/24/2012

Reckamp KL – With the approval of the antiangiogenic antibody bevacizumab in non–small cell lung cancer (NSCLC) and other malignancies, the tumor vasculature has emerged as a worthwhile therapeutic target. Second–line therapies have the potential to improve overall survival and quality of life over best supportive care alone.

Print Article Summary Cat 2 CME Report